Foundayo Trial Results Recast Eli Lilly Story On GLP1 Safety And Growth [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly (NYSE:LLY) reported positive phase 3 ACHIEVE-4 results for its once-daily oral GLP-1 therapy Foundayo (orforglipron) in at-risk type 2 diabetes patients. The trial showed reductions in body weight and blood sugar, and Foundayo matched or surpassed insulin glargine on cardiovascular outcomes. No liver safety signal was observed, addressing recent FDA concerns and the agency's request for additional safety data. Eli Lilly plans an imminent FDA submission for expanded use of Foundayo, targeting broader obesity and diabetes indications. Eli Lilly, through its GLP-1 portfolio, is positioned at the center of the growing obesity and diabetes treatment market, where oral options are drawing increased attention from patients and physicians. Foundayo's latest data arrives as regulators, clinicians, and investors compare different GLP-1 approaches and weigh convenience, safety, and long term outcomes across the drug class. For investors tracking NYSE:LLY, the ACHIEVE-4 resul
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- 2 Millionaire-Maker Stocks to Hold for the Next 10 Years [Yahoo! Finance]Yahoo! Finance
- Eli Lilly (LLY) Says FDA Requests Additional Data on Obesity Pill [Yahoo! Finance]Yahoo! Finance
- This Drug Stock Has Crushed the S&P 500 Over the Last Decade [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- This Drug Stock Has Crushed the S&P 500 Over the Last Decade [Yahoo! Finance]Yahoo! Finance
- Better Long-Term Buy: Eli Lilly or Viking Therapeutics? [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website